The American Diabetes Association (ADA) is committed to leading the fight against diabetes by funding research, and in June 2019 the results of the PIONEER 6 research trial on oral semaglutide were announced at the ADA’s 79th Scientific Sessions in San Francisco. Oral semaglutide offers an alternative to injection-based treatments of type 2 diabetes, and the results indicate oral semaglutide is a safe and effective treatment for individuals with type 2 diabetes who are also at high cardiovascular risk. The treatment led to an overall drop in mortality, including cardiovascular death, by almost 50 percent.
The study was conducted in 21 countries and featured 3,183 participants, with 85 percent of the participants age 50 or older with established CKD or CVD. Each day, the trail administered either a placebo or a 14 milligram dose of semaglutide to each participant.